ASH 2024 | Dr. Neha Mehta-Shah Discusses Challenges and Innovations in T-Cell Lymphoma Treatment

ASH 2024 | Dr. Neha Mehta-Shah Discusses Challenges and Innovations in T-Cell Lymphoma Treatment

2025.02.11
Significant progress has been made in the treatment of T-cell lymphomas in recent years. However, challenges persist in managing relapsed/refractory disease, selecting optimal therapies, and determining the best treatment sequencing for patients. To address these issues, the 2024 American Society of Hematology (ASH) Annual Meeting featured an educational session titled Addressing Unmet Needs in T-Cell Lymphomas. This session brought together leading experts to provide insights and practical guidance based on the latest research and clinical experiences. Hematology Frontier had the privilege of speaking with session chair Dr. Neha Mehta-Shah from Washington University’s Siteman Cancer Center. In this discussion, she shared her perspectives on unmet needs, treatment strategies for relapsed/refractory peripheral T-cell lymphoma (PTCL), innovative therapies, and the role of autologous and allogeneic transplants in PTCL.
Annual Review | Dr. Kan Gong: Advances in the Diagnosis and Treatment of Localized Prostate Cancer in 2024

Annual Review | Dr. Kan Gong: Advances in the Diagnosis and Treatment of Localized Prostate Cancer in 2024

2025.02.11
Prostate cancer is one of the most common malignancies threatening men's health worldwide. With population aging and lifestyle changes, the incidence of prostate cancer in China has been steadily increasing in recent years. As an early-stage disease, localized prostate cancer generally has a favorable prognosis, with curative potential through comprehensive treatment primarily centered on local interventions such as surgery. Enhancing the diagnosis and treatment of localized prostate cancer is key to improving overall survival rates for prostate cancer patients. Looking back at 2024, what were the major research advances in this field? This review will summarize key developments in screening and diagnosis, neoadjuvant therapy, surgical treatment, and the management of biochemical recurrence after surgery.
Annual Review | Addressing Unmet Needs: Dr. Qiang Wei on Advances in Bladder Cancer Treatment in 2024

Annual Review | Addressing Unmet Needs: Dr. Qiang Wei on Advances in Bladder Cancer Treatment in 2024

2025.02.11
Bladder cancer is one of the most common malignancies of the urinary system, posing a serious threat to public health in China. For patients with localized disease, repeated intravesical treatments and follow-up procedures require frequent hospital visits, while those who undergo surgery often face the lifelong challenge of urinary diversion. Patients with inoperable advanced bladder cancer also have limited treatment options, as traditional chemotherapy provides only modest benefits. These significant unmet medical needs—affecting both survival and quality of life—have driven continuous innovation in the field of bladder cancer treatment.